- Optiscan signs deal with world-renowned Mayo Clinic
- AdAlta designates Cell Therapies as its manufacturing partner
- Ecofibre jumps after entering sell and leaseback agreement in US
Optiscan signs deal with Mayo Clinic
Optiscan Imaging (ASX:OIL) jumped +27% this morning after announcing a know-how agreement with
Mayo Clinic aimed at developing a
digital confocal laser endomicroscopic imaging system tailored for application in
robotic surgery.
This collaboration will harnesses Optiscan’s extensive engineering proficiency in digital endomicroscopic hardware and software development, synergising with Mayo Clinic’s expertise in robotic surgery and patient care.
The deal will be for a 24-month period, where experts from both Optiscan and Mayo will collaborate to create a robot-compatible endomicroscopic imaging system, with an initial emphasis on robotic-assisted breast cancer surgery.
Mayo Clinic is the largest not-for-profit medical group practice in the world, and has earned top rankings for high-quality patient care with more #1 rankings than any other hospital in the US.
It’s also top-ranked in more specialties than any other US hospital. The hospital undertakes more than 141,000 surgical cases and performs more than 4,000 robotic surgery cases a year.
Meanwhile, the robotic-assisted surgery market is experiencing significant growth.
The US robotic surgery service market was valued at US$1.8bn in 2022, and is estimated to grow at a compound annual growth rate (CAGR) of 17.3% to reach US$6.4bn in 2030.
Optiscan CEO, Dr Camile Farah, said the collaboration is part of Optiscan’s wider strategic focus on the US market, and the company’s plan to embed its technology as a key component of oncological surgery workflows.
“This collaboration is built on a shared history of innovation and a laser focus on delivering the highest quality patient outcomes for better health care delivery,” added Dr Farah.
